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Evidences increasingly indicate the involvement of long non-coding RNAs (lncRNAs)
in various biological processes. As the mutations and abnormalities of lncRNAs
are closely related to the progression of complex diseases, the identification of
lncRNA-disease associations has become an important step toward the understanding
and treatment of diseases. Since only a limited number of lncRNA-disease associations
have been validated, an increasing number of computational approaches have been
developed for predicting potential lncRNA-disease associations. However, how to
predict potential associations precisely through computational approaches remains
challenging. In this study, we propose a novel two-side sparse self-representation (TSSR)
algorithm for lncRNA-disease association prediction. By learning the self-representations
of lncRNAs and diseases from known lncRNA-disease associations adaptively, and
leveraging the information provided by known lncRNA-disease associations and the
intra-associations among lncRNAs and diseases derived from other existing databases,
our model could effectively utilize the estimated representations of lncRNAs and diseases
to predict potential lncRNA-disease associations. The experiment results on three
real data sets demonstrate that our TSSR outperforms other competing methods
significantly. Moreover, to further evaluate the effectiveness of TSSR in predicting potential
lncRNAs-disease associations, case studies of Melanoma, Glioblastoma, and Glioma are
carried out in this paper. The results demonstrate that TSSR can effectively identify some
candidate lncRNAs associated with these three diseases.
Keywords: lncRNAs-disease associations prediction, computational approaches, sparse representation, lncRNA
similarity, disease similarity
1. INTRODUCTION
Long non-coding RNAs (lncRNAs), which are a class of non-coding transcripts with the lengths
longer than 200 nucleotides (Derrien et al., 2012; Harrow et al., 2012; Guttman et al., 2013; Chen
et al., 2016b), have been proven to be involved in various biological processes (Chen et al., 2012,
2016b, 2018) and closely correlated with the development of complex diseases, such as cancers
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and rheumatic diseases (Bussemakers et al., 1999; Managadze
et al., 2011; Bhartiya et al., 2012; Schonrock et al., 2012; Li
et al., 2013; Lu et al., 2013; Zhao et al., 2014; Chen et al.,
2016b). For example, studies have revealed the roles of lncRNAs
in regulating gene expression (Taft et al., 2010; Wapinski and
Chang, 2011). As the development of complex diseases are
closely related to the mutations and abnormalities of lncRNAs,
to understand the pathogenesis of human diseases systematically,
and identify the biomarkers of disease progression and prognosis,
it is important to predict the potential associations between
diseases and lncRNAs (Chen et al., 2016b; Yu et al., 2018).
However, only a small number of lncRNA-disease associations
have been validated. Therefore, efficient methods for predicting
the associations between lncRNAs and diseases are emergent
needed (Lu et al., 2018).
In recent years, identifying the associations between diseases
and lncRNAs has attracted a lot of attentions (Chen and Yan,
2013; Lu et al., 2018). Prediction methods based on biological
experiments or computational approaches are proposed to
undertake this task. Due to the limitations of biological
experiments such as time-consuming and expensive in cost,
computational approaches provide an alternative for biological
experiments and have been widely used to identify the
associations between lncRNAs and diseases (Chen et al., 2016b).
Existing computational approaches for association prediction
can be roughly classified into three categories. The first
category is based on machine learning approaches. These
models predict the associations between diseases and lncRNAs
based on known lncRNA-disease associations. For example,
Chen et al. proposed a semi-supervised learning-based method
named Laplacian Regularized Least Squares for LncRNA-disease
Association (LRLSLDA) (Chen and Yan, 2013) to predict
the associations between diseases and lncRNAs. Zheng et al.
formulated the problem of association prediction as a matrix
factorization problem and introduced a collaborative matrix
factorization model (CMF) (Zheng et al., 2013) to predict the
associations. However, the performance of machine learning-
based methods depend on the choice of hyperparameters such
as the dimensionality of the latent space in matrix factorization-
based methods, and the suitable values for these hyperparameters
are usually previously unknown and hard to determine.
The second category is based on random walk. These
models identify potential lncRNA-disease associations by
integrating known associations between diseases and lncRNAs
and similarities among diseases and lncRNAs. For example, Zhou
et al. predicted the associations between diseases and lncRNAs
by implementing random walk with restart on the constructed
similarity networks among lncRNAs and diseases (Zhou M.
et al., 2015). The third category is based on data integration.
These models focus on integrating multiple heterogeneous
data sources. For example, Lu et al. (2018) developed a model
named SIMCLDA for identifying the associations between
diseases and lncRNAs based on disease-gene and gene-gene
ontology associations. However, the above methods rely heavily
on the similarity networks or external information (e.g.,
similarity networks among diseases and lncRNAs, and gene-gene
associations) that are inferred based on predefined metrics.
Moreover, the information extracted from other databases or
data platforms may include some irrelevant or noise information
that may mislead the prediction of associations.
To address the above problems, in this paper, we introduce
a novel two-side sparse self-representation (TSSR) model
for lncRNA-disease association prediction. Based on known
lncRNA-disease associations, our model can adaptively learn
two non-negative sparse self-representation matrices which
capture the intra-similarities among lncRNAs and diseases
respectively. Moreover, our model could also drawn support
from the intra-associations among disease and lncRNAs that
derived from external information of lncRNAs and diseases
to generate more accurate estimation of the representation
matrices. Experiment results on three real datasets demonstrate
that compared with six state-of-the-art association prediction
algorithms, our TSSR model could achieve more accurate
prediction results. Furthermore, case studies on three cancers
(i.e., Glioblastoma, Glioma, and Melanoma) also demonstrate
the effectiveness of TSSR in predicting the associations between
lncRNAs and diseases. The source code of TSSR is available at
https://github.com/Oyl-CityU/TSSR.
The rest of this paper is organized as follows. In section
2, we formulate our two-side sparse self-representation model
and introduce a relaxed Majorization-Minimization algorithm to
solve the optimization problem. The experiment results and case
studies are given in section 3. In section 4, we conclude our works.
2. METHODS
2.1. Notations and Problem Statement
In this paper, we use D = {di}
m
i=1 to represent the set of lncRNAs
and T = {tj}
n
j=1 to represent the set of diseases, where m and
n denote the number of lncRNAs and the number of diseases,
respectively. A binary matrix Y = [Yij] ∈ {0, 1}
m×n is introduced
to represent the associations between lncRNAs and diseases,
where Yij = 1 if there is an association between lncRNA di and
disease tj, and Yij = 0 otherwise. Note that there are two reasons
that may lead to Yij = 0. The first reason is that it has been
experimentally verified that there is no association between di
and tj. The second reason is that whether there is an association
between di and tj is still unknown. Therefore, we usually refer to
the zero elements in Y as unknown pairs. The lncRNA-disease
association prediction problem can be formulated as the problem
of predicting the scores of unknown pairs in Y , which can be used
for ranking the pairs. In this study, we first rank the unknown
pairs in Y based on the predicted scores in descending order, and
then select the top-ranked pairs as potential association pairs.
In particular, unlike matrix factorization methods that project
lncRNAs and diseases into a shared latent space and predict
lncRNA-disease associations based on the inner product of
their latent vectors, we try to learn the intra-similarities among
lncRNAs and diseases from the observed associations in Y ,
and utilize the learned similarity matrices to reconstruct Y
and thus predict the scores of unknown pairs in Y . Here,
instead of using predefined metrics to construct the similarity
matrices of lncRNAs and diseases (which makes the predicted
results sensitive to the selected metrics and input data), we
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introduce a novel two-side sparse self-representation (TSSR)
model to adaptively learn the intra-similarities among lncRNAs
and diseases from the observed associations in Y , and effectively
utilize external information of lncRNAs and diseases to enhance
the prediction performance.
2.2. Two-Side Sparse Self-Representation
Model
Sparse representation techniques which focus on finding a sparse
representation of a sample in the form of a linear combination
of basic elements (also called atoms) in a dictionary, have
been widely used to numerous applications such as computer
vision and machine learning (Zhang et al., 2015). In traditional
sparse representation models, the objective is to solve the
following problem
min
x
‖x‖0 s.t. y = Dx. (1)
where ‖ · ‖0 denotes L0 norm, y ∈ R
m×1 is a sample vector, D
is a m × l matrix which denotes the dictionary and x ∈ Rl×1 is
the sparse representation coefficient of y. In practice, L0 norm
is usually replaced with L1 norm to make the above problem
(1) solvable in polynomial time. Since the above problem (1)
needs to take extra time to construct the dictionary D and has
not data-adaptiveness. Many approaches are proposed to employ
the dataset itself as the dictionary, which results in the following
sparse self-representation model
min
X
‖Y − YX‖2F + β‖X‖1. (2)
where ‖.‖F is the Frobenius norm, Y denotes the feature set of all
samples (each row denotes a feature and each column represents
the feature vector of a sample), X is the sparse self-representation
coefficient matrix of the columns of Y (each column X·j of X
denotes the representation coefficient of j-th sample Y·j, with
all samples in Y as dictionary) and β is a tuning parameter to
control the trade off between the minimization error and the
sparsity. By solving the above model (2), X can capture the most
similar relationships among the columns of Y , based on the
information provided in Y . In this study, Y ∈ {0, 1}m×n describes
the observed associations between lncRNAs and diseases and we
would like to predict potential associations between lncRNAs
and diseases based on their intra-similarities learned from Y .
Thus, instead of just finding the representations of the columns
of Y , we prefer to explore the representations of the rows and
columns ofY simultaneously, which capture the intra-similarities
within lncRNAs and diseases respectively. Based on the idea of
sparse self-representation, we introduce a novel two-side sparse
self-representation (TSSR) model to handle the task of lncRNA-
disease association prediction. In particular, we formulate the
framework of TSSR into the following optimization problem
min
U,V
‖Y − UYV‖2F + β(‖U‖1 + ‖V‖1),
s.t. U ≥ 0,V ≥ 0,
m∑
z=1
Uiz = 1,
n∑
k=1
Vkj = 1.
(3)
where U = [Uii′ ] ∈ R
m×m
+ and V = [Vjj′] ∈ R
n×n
+ are two non-
negative sparse matrices which represent the row and column
representation coefficient matrices of Y , respectively, and β is a
tuning parameter which controls the sparsity of U and V . Based
on this definition, U denotes the coefficient matrix based on the
dictionary YV , which captures the similarities among lncRNAs.
For example, Uii′ denotes the similarities between the i-th and
i′-th lncRNAs, which correspond to the i-th and i′-th rows of Y .
On the other hand, V denotes the coefficient matrix based on the
dictionary UY , which captures the similarities among diseases.
For example, Vjj′ denotes the similarities between the j-th and
j′-th diseases, which correspond to the j-th and j′-th columns
of Y . With the sparse regularization term, we can control the
sparsity of the learned representation matrices U and V , and
find the most similar relationships within lncRNAs and diseases.
The constraints
∑m
z=1 Uiz = 1 and
∑n
k=1 Vkj = 1 are used to
guarantee the probability properties of Ui· and V·j, respectively.
In the above objective function (3), the representation
matrices are learned from the original data matrix Y , which
means that they will be sensitive to the input data Y . If the input
data only includes a small number of known associations, it may
be hard to learn a comprehensive representation matrix. With
the development of high-throughput experimental techniques
and the accumulation of clinical information, we could also
collect some functional annotations and phenotype information
for lncRNAs and diseases respectively. Based on these prior
information, we can infer the intra-associations among diseases
and lncRNAs. To utilize these pairwise associations inferred from
other databases to promote the estimation of two representation
coefficient matrices U and V , two regularization terms are added
to Equation (3). Moreover, we introduce a weight matrix W
in a similar way to Zheng et al. (2013) to prevent unknown
instances (for which association information is not available)
from contributing to the determination of the row and column
representations of Y (i.e., U and V). The final objective function
of our TSSR model is as follows.
min
U,V
‖W ⊙ (Y − UYV)‖2F + β(‖U‖1 + ‖V‖1)
+ λd‖Sd − U‖
2
F + λt‖St − V‖
2
F ,
s.t. U ≥ 0,V ≥ 0,
m∑
z=1
Uiz = 1,
n∑
k=1
Vkj = 1.
(4)
where λd and λt are two tuning parameters controlling the
influences of prior intra-associations among lncRNAs and
diseases, Sd ∈ R
m×m and St ∈ R
n×n denote the affinity matrices
of lncRNA and disease respectively, where (Sd)ii′ describes the
association between lncRNAs di and di′ , and (St)jj′ describes
the associations between diseases tj and tj′ . ⊙ denotes the
element-wise product or Hadamard product of two matrices and
W ∈ Rm×n is a weight matrix where Wij = 0 for unknown
entries in Y and Wij = 1 for known entries in Y . Consequently,
unknown entries in Y do not contribute to the minimization of
the first term of Equation (4).
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2.3. Optimization Algorithm
Here, to handle the constraints in (4), we employ a relaxed
Majorization-Minimization algorithm (Yang and Oja, 2011,
2012) to obtain the solution of objective function (4). For more
details about this optimization method, please refer to Yang and
Oja (2012). In particular, we denote ▽U as the gradient of our
objective function with respect to U.
▽U = −2[W ⊙ (Y − UYV)]V
TYT − 2λd(Sd − U)+ β . (5)
Let ▽+U = 2W ⊙ (UYV)V
TYT + 2λdU + β and ▽
−
U = 2(W ⊙
Y)VTYT + 2λdSd denote the positive and negative parts of ▽U ,
respectively. Thus, we have▽U = ▽
+
U −▽
−
U .
Due to the constraint
m∑
z=1
Uiz = 1 and Uiz ≥ 0, we obtain the
following updating rule for Uiz :
Unewiz = Uiz ·
aUi (▽
−
U )iz + 1
aUi (▽
+
U )iz + b
U
i
. (6)
where aUi and b
U
i can be obtained by Equations (7) and
(8), respectively.
aUi =
∑
z
Uiz
(▽+U )iz
, (7)
bUi =
∑
z
Uiz
(▽−U )iz
(▽+U )iz
. (8)
Similarly, we denote▽V as the gradient of our objective function
with respect to V .
▽V = −2(Y
TUT)[W ⊙ (Y − UYV)]− 2λt(St − V)+ β . (9)
Let ▽+V = 2Y
TUT[W ⊙ (UYV)] + 2λtV + β and ▽
−
V =
2YTUT(W⊙Y)+ 2λtSt denote the positive and negative parts of
▽V , respectively, we have▽V = ▽
+
V −▽
−
V .
Similarly, the updating rule for Vkj is as follows:
Vnewkj = Vkj ·
aVj (▽
−
V )kj + 1
aVj (▽
+
V )kj + b
V
j
. (10)
where aVj =
∑
k
Vkj
(▽+V )kj
and bVj =
∑
k Vkj
(▽−V )kj
(▽+V )kj
.
The details of the optimization algorithm to the proposed TSSR
model are described in Algorithm 1. U and V can be updated
by Equations (6) and (10), respectively. In this study, we stop
the iteration when the changes of U and V are less than 1e-
6, measured by L1 norm. Finally, the predicted label matrix Yˆ
can be returned by Yˆ = UYV when algorithm arrives at the
convergence conditions.
Algorithm 1: Algorithm for the TSSR model
• Inputs: Partial label matrix Y , lncRNA affinity matrix Sd,
disease affinity matrix St , tuning parameter λd, λt ,β , weight
matrixW.
• Output: Predicted label matrix Yˆ .
• Main algorithm:
1. Initialize U and V ;
2. While not converged do
3. Update U according to Equation (6)
Unewiz = Uiz ·
aUi (▽
−
U )iz + 1
aUi (▽
+
U )iz + b
U
i
;
4. Update V according to Equation (10)
Vnew
kj
= Vkj ·
aVj (▽
−
V )kj + 1
aVj (▽
+
V )kj + b
V
j
;
5. Check the convergence conditions.
6. End while
7. Return Yˆ = UYV .
3. RESULTS
In this section, we demonstrate the performance of various
algorithms on three real datasets. Furthermore, case studies of
three cancer diseases (i.e., Melanoma, Glioblastoma, and Glioma)
are performed to validate the effectiveness of our TSSR model.
The materials, experimental settings, and parameter settings are
described as follows.
3.1. Materials
3.1.1. LncRNA-Disease Associations
We collect three datasets to evaluate the performance of various
prediction algorithms. The first dataset is downloaded from the
supplementary data of a article (Lu et al., 2018), which contains
621 experimentally confirmed lncRNA-disease associations
between 226 diseases and 285 lncRNAs from the LncRNADisease
database1 established in 2015. The second dataset involving 260
high-quality associations between 95 lncRNAs and 81 human
disease is obtained from the supplementary files of the published
article (Chen et al., 2015), which retrieved data from MNDR
database2 (Wang et al., 2013) in March 2015 . The third dataset
is downloaded from the Lnc2Cancer database 3 in 2015. By
getting rid of the duplicate lncRNA-disease associations for the
same lncRNA-disease pair, we obtain 677 distinct associations,
including 54 human cancers and 436 lncRNAs. The statistics of
the three datasets are illustrated in Table 1.
3.1.2. Disease Similarities
As previous studies have discovered that diseases with similar
phenotypes are usually related with similar dysfunctions of
lncRNAs (Chen et al., 2015), incorporating the similarities among
diseases estimated from other database may help to infer the
1http://www.cuilab.cn/lncrnadisease
2http://www.rna-society.org/mndr/
3http://www.bio-bigdata.com/lnc2cancer/
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TABLE 1 | The statistics of three datasets.
Datasets No.of lncRNA No.of disease No.of associations Density
LncRNA Disease 285 226 621 0.01
MNDR 95 81 260 0.03
Lnc2Cancer 436 54 677 0.03
potential associations between diseases and lncRNAs based on
known lncRNA-disease associations. Similar to previous studies
(Wang et al., 2010; Chen et al., 2015), we construct the similarity
matrix St of diseases by integrating the disease semantic similarity
matrix inferred from the structure of directed acyclic graph that
describes the relationships among diseases (Wang et al., 2010;
Chen et al., 2015) and disease Gaussian interaction profile kernel
similarity matrix inferred from known associations between
diseases and lncRNAs (Chen and Yan, 2013; Chen et al., 2015).
In particular, we obtain the similarity matrix St by averaging the
disease similarity matrix and disease Gaussian interaction profile
kernel similarity matrix (van Laarhoven et al., 2011; Chen and
Yan, 2013; Chen et al., 2015, 2016a).
3.1.3. LncRNA Similarities
Since lncRNAs with similar functions tend to exhibit similar
associations with diseases, calculating the similarities among
lncRNAswill promotes the identification of potential associations
between diseases and lncRNAs. In this study, we calculate the
similarity matrix Sd of lncRNAs by integrating the functional
similarity matrix calculated by the model of LNCSIM (Chen
et al., 2015) and the lncRNA Gaussian interaction profile kernel
similarity matrix estimated from known associations between
lncRNAs and diseases (Chen and Yan, 2013). Similar to the
disease similarity matrix St , we obtain the lncRNA similarity
matrix Sd by averaging the lncRNA functional similarity matrix
and Gaussian interaction profile kernel similarity matrix (van
Laarhoven et al., 2011; Chen and Yan, 2013; Chen et al., 2015;
Chen et al., 2016a).
3.2. Experimental Settings
To illustrate the effectiveness of our proposed TSSR model, we
compare our method with other six state-of-the-art association
prediction methods, namely NetlapRLS (Xia et al., 2010), BLM-
NII (Mei et al., 2012), CMF (Zheng et al., 2013), PBMDA (You
et al., 2017a), PRMDA (You et al., 2017b), and SIMCLDA (Lu
et al., 2018). All these methods are designed for predicting the
inter-associations between different types of biological entities
and all of them can make use of the prior intra-associations
among biological entities to improve their performance. Thus,
all these algorithms are well suited for undertaking the
task of lncRNA-disease association prediction. Moreover, our
experiment results show that they are effective in inferring
the associations between diseases and lncRNAs. Specifically, 15
repetitions of 10-fold cross validation (CV) are conducted for
each model, with receiver operating characteristic (ROC) curve
as the main metric to evaluate the performance. By stacking the
columns of matrix Y , we obtained the vector, a mn × 1 vector,
denoted as vec(Y). In each repetition of 10-fold CV, we divide
vec(Y) into ten disjoint folds randomly. Nine folds are treated
as the training set while the remaining one fold is left out as
the testing set. The AUC (Area Under Curve) score is calculated
for each 10-fold CV repetition, and the final AUC score for each
model are obtained by averaging over 15 such repetitions.
3.3. Parameter Settings
As each model has some hyperparameters that need to be
predefined, we perform cross validation on the training set to
determine the values of these hyperparameters. In particular, the
parameter settings for various models are described as follows.
For NetLapRLS (Xia et al., 2010), the hyperparameters satisfy
γd2
γd1
=
γp2
γp1
, βd = βp with their values chosen from {10
−6, 10−5,
. . . , 102}. For BLM-NII (Mei et al., 2012), the value of the linear
combination weight α is chosen from {0, 0.1, 0.2, . . . , 1.0}.
The max function is utilized to combine the interaction scores
inferred from the disease and lncRNA sides. For the matrix
factorization based methods, the dimensionality of the latent
space K is selected from {50, 100} (Zheng et al., 2013). For CMF
(Zheng et al., 2013), the regularization coefficient λ1 is chosen
from {2−2, . . . , 21} (Zheng et al., 2013), while the values of λd
and λt are chosen from {2
−3, 2−2, . . . , 25}. For PBMDA (You
et al., 2017a), the maximum path length L is set to 3 and the
weight threshold T is selected from {0.2, 0.3, . . . , 0.8} with the
step size set to 0.1, while the decay factor α is set to 2.26. For
SIMCLDA (Lu et al., 2018), we set the values of αl and αd from
0.1 to 1 with stepsize 0.1 and select the regularization parameter
from {10−3, 10−2, . . . , 103}. For TSSR, we choose the three
parameters β and λd = λt from {2
−10, 2−9, . . . , 29, 210}. Note
that the most suitable hyper-parameters of a machine learning
model on different datasets are usually different. Therefore,
in this work, we adopt grid search (Bergstra and Bengio,
2012) to select the optimal hyperparameters for each model on
each dataset.
3.4. Comparison With State-of-the-Art
Methods
We conduct the experiments with 10-fold CV to shed light
on the performance of TSSR in predicting potential lncRNA-
disease associations, compared with other six state-of-the-
art methods. Here, the AUC score is used to evaluate the
predictive performance of various methods. The experiment
results measured by AUC are shown in Figures 1–3. As shown
in Figure 1, on LncRNADisease dataset, TSSR obtains an AUC
score of 0.8736, which is higher than other methods (BLM-
NII 0.8641, NetLapRLS 0.7837, CMF 0.7273, PBMDA 0.6885,
PRMDA 0.7231, SIMCLDA 0.6067), indicating the superiority
of our TSSR in predicting lncRNA-disease associations. We can
find from Figure 2 that on MNDR dataset, TSSR achieves the
best AUC score (TSSR 0.8369, BLM-NII 0.7929, NetLapRLS
0.8210, CMF 0.8078, PBMDA0.7722, PRMDA0.6596, SIMCLDA
0.6187). On Lnc2Cancer dataset (the results are shown in
Figure 3), TSSR still has competitive performance with other
six methods with respect to AUC score (TSSR 0.9814, BLM-
NII 0.9859, NetLapRLS 0.9392, CMF 0.9864, PBMDA 0.9680,
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PRMDA 0.8179, SIMCLDA 0.6190). Note that on Lnc2Cancer,
our TSSR achieves similar performance with BLM-NII and CMF.
This may due to the parameter setting of TSSR. In this study,
the values of the hyperparameters λd and λt (which control
the influences of prior intra-similarities among lncRNAs and
diseases) in our TSSR are set to same for simplicity, which is
reasonable when the two data sets are balanced. However, the
number of lncRNAs and diseases in Lnc2Cancer dataset are
imbalanced. Thus, forcing λd and λt to be equal may limit the
performance of TSSR. If the values of λd and λt are tuned
separately, TSSR could achieve better performance. Moreover, to
evaluate the effect of external information on the performance
of TSSR, we remove the regularization terms related to the
external information (i.e., setting λd = λt = 0) and show the
results in Figure 4. As shown in this figure, the performance
of TSSR and TSSR without external information (denoted by
TSSR_original) is comparable (on LncRNADisease, TSSR 0.8736,
TSSR_original 0.8735; on MNDR, TSSR 0.8369, TSSR_original
0.8367; on Lnc2Cancer, TSSR 0.9814, TSSR_original 0.9614),
whichmeans the improved performance of TSSR is mainly due to
the self-representation learning. Thus, our TSSR does not depend
heavily on the external information. All these results demonstrate
the effectiveness of the proposed TSSR in predicting potential
lncRNA-disease associations.
3.5. Effects of Parameters
The proposed TSSR involves three parameters, λd, λt , and β ,
where λd and λt control the influences of prior intra-associations
among lncRNAs and diseases and β controls the sparsity of
U and V . We will study how these parameters affect the
performance of TSSR.
Figure 5 shows the prediction performance of TSSR on
LncRNADisease dataset, MNDR dataset and Lnc2Cancer
dataset, measured by AUC with respect to different values
of λd and λt . As shown in Figure 5, the optimal value
of λd = λt for these three datasets is 2
−10, 20, and 22,
respectively, while β is set to 21, 28, and 28, respectively.
We find that TSSR usually performs well when the
values of λd and λt are relatively small, which means the
additional use of external information is not always helpful
for performance improvement. On the contrary, if the
external information contains noise, the performance of
TSSR may decrease if we overemphasizing the effect of
external information. These results demonstrate that our
TSSR can effectively learn the representation matrices from
known lncRNA-disease associations, and flexibly utilize
external information to promote the prediction of potential
lncRNA-disease associations.
In addition, we also study the impact of sparsity control
parameter β . Figure 6 illustrates the AUC scores obtained
by TSSR in terms of different values of β . As shown in
Figure 6, on these three datasets, TSSR achieves the best AUC
score when the value of β is 21, 28, and 28, respectively,
while λd = λt is set to 2
−10, 20, and 22, respectively.
We can also find from this figure that larger values of β
can generally achieve better performance, which indicates the
importance of controlling the sparsity of the representation
matrices U and V .
3.6. Case Studies
To further validate the performance of our algorithm, based
on the LncRNADisease dataset, we apply our TSSR model
to identify the most possible lncRNAs that associated with
three cancers (i.e., Melanoma, Glioma, and Glioblastoma).
Here, all the known associations in the LncRNADisease
dataset are used to train the model. Then we select the
top 20 associated lncRNAs which get the highest predicted
ranks for each cancer and verify these predictions based on
MNDR and Lnc2Cancer databases. Moreover, the relevant
literatures that support the prediction results are listed to
indicate whether the predicted lncRNA-disease associations
have been experimentally validated. Specially, MNDR database
contains both experimental and prediction evidence (Ning
et al., 2016; Ping et al., 2018). The results for the three
cancers are shown in Tables 2–4, respectively. Note that
we only show the predictions that are not included in
the training set.
Melanoma is a deadly malignancy which develops from
the pigment-containing cells with increasing incidence than
that of any other types of cancer (Aladowicz et al., 2013).
People with low level of skin pigment exposure in excess
ultraviolet light (UV) have a high risk to be infected a melanoma
(Kanavy and Gerstenblith, 2011). It has been estimated that
by 2030, melanoma could overtake colorectal cancer as the
fifth most common cancer (Rahib et al., 2014). Therefore, we
apply our TSSR model to predict the potential melanoma-
associated lncRNAs. According to the results shown in Table 2
(the complete list of the top 20 identified lncRNAs is shown
in Supplementary Material), 10 out of the top 20 identified
lncRNAs have been verified. For example, Luan et al. (2016)
discovered that MALAT1 could promote the cell proliferation,
invasion and migration of melanoma. Li et al. observed that
MEG3 was obviously decreased in melanoma cells (Li et al.,
2018). They also found melanoma cell apoptosis was induced by
up-regulation of MEG3, and consequently come to a conclusion
that overexpression of MEG3 has a significant repression impact
in melanoma cell migration and invasion ability.
Glioma is one of themost common primarymalignant tumors
originating in the brain, which comprises approximately 30% of
all brain tumors (Goodenberger and Jenkins, 2012; Boele et al.,
2015). Glioma can be graded from I to IV by World Health
Organization (WHO) grading system according to their grade
(Louis et al., 2016a,b). The exact causes of glioma are still unclear
at the present (Kwiatkowska and Symons, 2013; Li et al., 2015).
Studies have revealed the roles of lncRNAs in the development
of human disease, including glioma (Zhou et al., 2018). Here, we
utilize the TSSR to identify the potential lncRNAs that are more
likely to related to glioma. Based on the experiment results, 9
out of the top 20 identified lncRNAs have been validated in the
MNDR and Lnc2Cancer databases, and other relevant literatures.
The results are shown in Table 3 (the complete list of the top
20 identified lncRNAs is shown in Supplementary Material).
For example, Ma et al. discovered that compared with paired
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FIGURE 1 | AUC scores of various algorithms in LncRNADisease dataset (* indicates TSSR significantly outperforms the competitor with p < 0.05 using t-test, error
bars denote 95% confidence intervals).
FIGURE 2 | AUC scores of various algorithms in MNDR dataset (* indicates TSSR significantly outperforms the competitor with p < 0.05 using t-test, error bars
denote 95% confidence intervals).
normal tissues, the expression level of lncRNA MALAT1 was
increased in glioma tissues, whichmeansMALAT1 can be treated
as a convictive marker for the prognosis of glioma patients
(Ma et al., 2015). Zou et al. revealed that glioma patients with
high PVT1 expression had low survival rate (Zou et al., 2017).
Moreover, patients who received chemotherapy and radiotherapy
could improve their survival by down-regulating PVT1. They
also indicated that PVT1 could be served as potential target for
the treatment of diffuse gliomas.
Glioblastoma, also known as glioblastoma multiform (GBM)
(grade IV of Glioma), is the most common and aggressive
form of primary brain tumors and kills nearly every patient in
a median time of 15 months (Bleeker et al., 2012; Jovcˇevska
et al., 2013). More importantly, there is still no clear way to
prevent the disease (Gallego, 2015). Therefore, it is urgent to
predict the potential glioblastoma-associated lncRNAs. In this
study, we use our TSSR to undertake this task. As shown
in Table 4, 8 out of the 20 lncRNAs have been verified in
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FIGURE 3 | AUC scores of various algorithms in Lnc2Cancer dataset (* indicates TSSR significantly outperforms the competitor with p < 0.05 using t-test, error bars
denote 95% confidence intervals).
FIGURE 4 | Performance of TSSR with and without external information (denoted by TSSR and TSSR_original, respectively) on LncRNADisease, MNDR, and
Lnc2Cancer datasets, measured by AUC (error bars denote 95% confidence intervals).
FIGURE 5 | Performance of TSSR on LncRNADisease, MNDR, and Lnc2Cancer datasets, measured by AUC with different values of λd and λt (error bars denote
95% confidence intervals).
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FIGURE 6 | Performance of TSSR on LncRNADisease, MNDR, and Lnc2Cancer datasets, measured by AUC with different values of β (error bars denote 95%
confidence intervals).
TABLE 2 | The identified novel lncRNAs that have been verified to be associated with Melanoma.
Rank lncRNA Evidence(Database) Evidence(PMID) Expression pattern
1 CCAT2 MNDR Prediction evidence
2 TUSC7 MNDR Prediction evidence
9 GHET1 MNDR Prediction evidence
12 MEG3 MNDR/lnc2Cancer 29781534,29808164 Up-regulated, differential expression
13 HOTAIR MNDR/lnc2Cancer 28067428,23862139 up-regulated
14 SOX2-OT MNDR Prediction evidence
15 MALAT1 MNDR/lnc2Cancer 27725873, 27564100,27966454,24892958,19625619 Up-regulated,differential expression
17 SNHG5 MNDR/lnc2Cancer 26440365 Up-regulated
18 BCAR4 MNDR Prediction evidence
19 CCAT1 lnc2Cancer 28409554 Up-regulated
Prediction evidence denotes the prediction associations in MNDR database.
TABLE 3 | The identified novel lncRNAs that have been verified to be associated with Glioma.
Rank lncRNA Evidence(Database) Evidence(PMID) Expression pattern
2 HOTAIR MNDR/lnc2Cancer 29323737,28083786 ,29218099, 27277755,24203894 Up-regulated, down-regulated
3 MALAT1 MNDR/lnc2Cancer 28551849,27134488,26649728,25613066,26619802 Up-regulated, down-regulated
4 GAS5 MNDR/lnc2Cancer 26370254,28666797 Up-regulated, down-regulated
7 PVT1 lnc2Cancer 28351322,29108264,29620147,29501773,29046366 Up-regulated, differential expression
11 SPRY4-IT1 MNDR/lnc2Cancer 29467908,27460732,26464658 Up-regulated
12 GHET1 MNDR Prediction evidence
15 IGF2-AS MNDR Prediction evidence
18 LincRNA-p21 lnc2Cancer 28689810 Down-regulated
19 SNHG4 MNDR Prediction evidence
Prediction evidence denotes the prediction associations in MNDR database.
the MNDR and Lnc2Cancer databases, and other relevant
literatures (the complete list of the top 20 identified lncRNAs
is shown in Supplementary Material). For example, Zhou et al.
described that HOTAIR has a significant increased expression
in multiple human cancers including GBM and they found
HOTAIR is necessary for GBM formation in vivo (Zhou X.
et al., 2015). Thus, HOTAIR could be a potential therapeutic
target in glioblastoma. Liu et al. found that NBAT1 has lower
expressions in glioblastoma tissues compared with those in
normal brain tissues and they also observed that up-regulated
NBAT1 inhibits proliferation of T98 and U87 cells via regulating
Akt, suggesting that NBAT1 may be related to prognosis of
glioblastoma (Liu et al., 2018).
Based on the above case studies, we find that our TSSR
is effective in identifying novel associations between lncRNAs
and diseases based on known lncRNA-disease associations and
intra-associations among lncRNAs and diseases.
4. CONCLUSION
Increasing evidences indicate the role of lncRNAs in biological
processes, which motivates the development of computational
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TABLE 4 | The identified novel lncRNAs that have been verified to be associated with Glioblastoma.
Rank lncRNA Evidence(Database) Evidence(PMID) Expression pattern
1 MEG3 MNDR/lnc2Cancer 27306825,28187000,22234798,25378224,26111795 Up-regulated
2 HOTAIR MNDR/lnc2Cancer 27306825,25428914,25823657,26111795,26943771 Up-regulated
6 BCYRN1 MNDR 25561975 Differentially expressed
8 GAS5 MNDR/lnc2Cancer 27784795,23726844 Up-regulated, differentially expressed
10 NEAT1 lnc2Cancer 23046790 Up-regulated
11 HIF1A-AS2 MNDR/lnc2Cancer 27264189 Up-regulated
15 NBAT1 lnc2Cancer 29771423 Up-regulated
17 NDM29 MNDR 25561975 Differentially expressed
Prediction evidence denotes the prediction associations in MNDR database.
models to identify the potential associations between lncRNAs
and diseases. Predicting the potential associations between
lncRNAs and diseases based on known lncRNA-disease
associations is equivalent to a recommendation problem with
implicit feedback, where the task is to predict whether the
unknown pairs in Y are potential associations or not. In
this paper, we present a novel model, named two-side sparse
self-representation (TSSR), to predict the scores of unknown
pairs in Y . Based on these predicted scores, we could identify
potential associations between lncRNAs and diseases. Unlike
previous matrix factorization techniques that project lncRNAs
and diseases into a shared latent space and predict lncRNA-
disease associations based on the inner product of their latent
vectors (where the dimension of latent space is previously
unknown and hard to determine), our model directly learn
the intra-similarities among lncRNAs and diseases from the
observed associations in Y , and utilize the learned representation
matrices to reconstruct Y by regarding original Y as a dictionary.
As shown in Equation (4), our TSSR does not need to make
many assumptions of the model in advance. Moreover, by
forcing the representation matrices to be sparse, our TSSR
could learn the most similar relationships among lncRNAs
and diseases based on the observed associations in Y . Thus,
our TSSR has data-adaptiveness and avoids the determination
of some sensitive parameters such as the dimension of latent
space and number of nearest neighbors. Unlike random walk-
based or data integration-based methods that rely heavily on
the similarity networks inferred from external information
with predefined metrics, our model could adaptively learn the
self-representations of lncRNAs and diseases according to their
performance in reconstructing observed associations in Y .
Moreover, in case the input data Y only includes a small number
of known associations, our model could draw support from the
intra-associations among lncRNAs and diseases derived from
external information to enhance the learning of representation
matrices. Therefore, our model could effectively predict potential
lncRNA-disease associations by leveraging the information
provided by known lncRNA-disease associations and external
information of lncRNAs and diseases. Experiment results on
three real data sets show that our TSSR could achieve better
performance than other six state-of-the-art methods. The
effectiveness of TSSR in predicting potential lncRNA-disease
associations is also evaluated based on three case studies.
As a link prediction algorithm, our TSSR model is flexible
and could be used to handle other link prediction tasks in
bipartite networks.
Furthermore, since external information of lncRNAs and
diseases are utilized to enhance the performance of various
methods, we also perform sensitivity analysis to assess the
influences of noise information on the performances of
various methods. In particular, we generate the similarity
matrices Sd and St randomly (i.e., the elements in Sd and
St are generated randomly) and test the performances
of various methods. The detailed experiment results
are shown in Tables S4–S6. As shown in these tables,
although the performance of TSSR is affected by the noise
information, it could still achieve the best performance,
which means our TSSR could be used to undertake the
lncRNA-disease prediction task even when the collected
external information of lncRNAs and diseases contains a
lot of noise.
With the development of high-throughput experimental
techniques, an increasing number of data for lncRNAs and
diseases are becoming available. We can calculate the similarities
among lncRNAs (or diseases) based on different views of data
and different metrics. How to efficiently seek the optimal
combination of these similarities is an interesting future work.
We will try to extend our model to handle this problem.
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